Recording now availble!
Presented: Aug. 23, 2016
Duration: 2 hours
AHPA-CRN Members - FREE
Non-Members - $99
Presented in cooperation with IADSA
AHPA has partnered with the Council for Responsible Nutrition (CRN) to present a webinar that guides U.S. supplement companies through the uncertainty created by the United Kingdom's (UK's) decision to leave the European Union (EU), commonly referred to as Brexit.
Simon Pettman, the executive director of the International Alliance of Dietary Supplement Associations (IADSA), Brian Kelly, Esq., associate in the London Life Sciences group at Covington & Burling LLP, and Gert Krabichler, Ph.D., global head regulatory policy and intelligence at Merck Selbstmedikation / Merck Consumer Health, will discuss the implications of Brexit for the marketing of food supplements, including:
Why the vote?
This is the first time in the EU's history that a country has decided to leave. Understanding the background to this vote and the dynamics of this is important to understanding the likely next steps.
Why did the UK vote to leave the EU?
52% of those who voted, wanted to leave or at least they voted to leave. This left 48% wishing to remain a member. For a vote which has potentially the greatest political and economic implications of any vote in the UK in the lifetimes of most British people, this was not an overwhelming mandate. Understanding who wanted to remain and why is as important as understanding those who voted to leave. This issue is now set to run through the political culture of the UK for the next decade and more.
What are the current options for the UK and the EU?
This is uncharted territory for all sides and the negotiations can go in many directions with potentially large political and economic risks attached.
What is the probable process and timing?
What could the UK's departure from the EU mean for EU and UK policy making in the supplement area?
The UK has been an important and highly influential country in the EU since its membership. Often it has shown itself to be more pro-business than many other Member States. So, how will this impact the development of legislation and science in an EU with 27 Member States and what will this mean for UK policy making as it goes it alone.
What should companies selling into the UK or manufacturing in the UK be watching for?
The pressure from business for an orderly, sensible and open approach is strong, although most major companies are quietly deeply worried about the coming years. But there are still some potentially significant risks ahead that need to be monitored by any business engaged in the UK.
AHPA and CRN are presenting this free webinar as a member benefit.